According to DelveInsight’s epidemiology model, the total diagnosed prevalent cases of Parkinson’s disease were approximately ...

also partnered with UCB – and felzartamab, an anti-CD38 antibody for IgA nephropathy (IgAN) and other diseases, licensed from Human Immunology Biosciences (HI-Bio) for $1.15 billion upfront ...

Belgian pharmaceutical company UCB is dropping its development of minzasolmin ... Earlier this year, Annovis Bio announced that its investigational candidate buntanetap tartrate was successful ...

Researchers from UCB SA and affiliated organizations presented the discovery and preclinical characterization of novel NUAK family SnF1-like kinase-1 (NUAK1) inhibitors for the treatment of central ...